CAS 287714-41-4: Rosuvastatin

Rosuvastatin is a synthetic lipid-lowering agent, which is a product of pharmaceutical manufacturing derived from extensive research in cardiovascular pharmacology. It functions as an HMG-CoA reductase inhibitor, effectively blocking the enzyme responsible for cholesterol biosynthesis in the liver. By inhibiting this enzyme, Rosuvastatin reduces the production of cholesterol, especially low-density lipoprotein (LDL) cholesterol, which is known to contribute to atherosclerosis. Its primary use is in the management of hypercholesterolemia and related conditions, aimed at reducing cardiovascular morbidity and mortality. Clinical studies have demonstrated its efficacy in not only lowering LDL cholesterol but also in raising high-density lipoprotein (HDL) cholesterol and reducing triglycerides. Furthermore, Rosuvastatin has applications in primary prevention among patients at risk for coronary artery disease, as well as in secondary prevention in those with established cardiovascular disease. Its pharmacokinetic properties, including a long half-life and minimal drug-drug interaction, make it a well-tolerated choice among statins. Continued research is expanding its clinical applications, examining benefits beyond lipid modulation.

Applications (3S,5S)-5-((S)-8-Fluoro-4-isopropyl-2-(N-methylmethylsulfonamido)-5,6-dihydrobenzo[h]quinazolin-6-yl)-3,5-dihydroxypentanoate Sodium Salt is an impurity of Rosuvastatin (R700500), a selective, competitive HMG-CoA reductase inhibitor. Antilipemic. References Watanabe, M., et al.: Bioorg. Med. Chem., 5, 437 (1997); Lee, E., et al.: Clin. Pharmacol. Ther., 78, 330 (2005); Ferdinand, K.C., et al.: Am. J. Cardiol., 97, 229 (2006)

Rosuvastatin (ZD4522) is an inhibitor of HMG-CoA reductase (HMGCR). Rosuvastatin has hypolipidemic and antiatherosclerotic effects. Cost-effective and quality-assured.

Rosuvastatin